Targeting calcium channels to reduce dyskinesia in Parkinson's disease
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD
This study is exploring a new way to help people with Parkinson's disease who experience troublesome movements caused by their medication, aiming to reduce these side effects while still keeping the benefits of their current treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11094926 on NIH RePORTER |
What this research studies
This research investigates a new approach to alleviate levodopa-induced dyskinesia (LID), a common and debilitating side effect of Parkinson's disease treatment. By using a method that reduces the expression of specific calcium channels in the brain, the researchers aim to prevent or reverse LID while maintaining the benefits of existing Parkinson's therapies. The study involves testing this approach in both animal models and nonhuman primates to assess its effectiveness and safety. Patients may benefit from a more effective treatment option that minimizes adverse effects associated with current medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who experience levodopa-induced dyskinesia.
Not a fit: Patients who do not have Parkinson's disease or do not experience dyskinesia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from dyskinesia related to Parkinson's disease.
How similar studies have performed: Previous research has shown promise in targeting calcium channels for similar therapeutic benefits, suggesting a potential for success in this approach.
Where this research is happening
East Lansing, United States
- Henry Ford Health + Michigan State University Health Sciences — East Lansing, United States (Active)
Researchers
- Principal investigator: Steece-Collier, Kathy — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Steece-Collier, Kathy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.